Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML.

ABSTRACT:

Introduction

The treatment landscape of chronic myeloid leukemia (CML) has evolved with the introduction of second- and third-generation tyrosine kinase inhibitors (TKIs), oCering potential advantages over imatinib. We analyzed prescription trends and public awareness of TKIs to assess the adoption of newer agents.

Methods

Monthly US prescription data from the IQVIA National Prescription Audit (NPA) and Google Trends search volumes from March 1, 2017, to November 31, 2024, were analyzed for visual and quantitative trends and correlation patterns. Studied TKIs included imatinib (first generation), dasatinib, bosutinib, nilotinib (second generation), and ponatinib, asciminib (third generation).

Results

Second-generation TKIs increased by 14.4% (15,171 to 17,363 average

SUBMITTER: Schroer AE 

PROVIDER: S-EPMC12665558 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature